Why TransMedics Stock Plunged in October

Source The Motley Fool

Shares of TransMedics (NASDAQ: TMDX), a biotech company that specializes in organ transportation, were tumbling last month after it issued disappointing results in its third-quarter update.

TransMedics shares had been soaring prior to the report as investors saw it as a disruptor in the industry, and it has put up impressive top-line growth.

The third-quarter results called the valuation into question as the company's growth slowed faster than expected. According to data from S&P Global Market Intelligence, the stock finished the month down 48%. As you can see from the chart below, the stock declined through the first few weeks of the month and then plunged on the earnings report at the end of October.

TMDX Chart

TMDX data by YCharts

TransMedics takes a dive

There wasn't any clear reason for TransMedics' pullback over the first few weeks of October as the broad market was mostly flat. Interest rates rose over the course of the month, which can put pressure on high-growth, low-profit stocks like TransMedics. However, the main news on the stock came in its third-quarter earnings report at the end of the month.

Revenue in the quarter jumped 64% to $108.8 million, which was short of the analyst consensus of $115 million. Management said the jump in revenue was driven by an increase in the utilization of its Organ Care System (OCS), and helped by additional revenue from its logistics services.

Gross margin slipped from 61% to 56% as more of the company's revenue continues to shift from product to services. Services revenue jumped 130% in the quarter to $42.9 million. On the bottom line, adjusted earnings per share came in at $0.12, significantly worse than the consensus at $0.29.

CEO Waleed Hassanein said, "We continued to make meaningful progress across each of our growth initiatives through the third quarter and maintain our conviction in our growth runway for 2025 and beyond." The company stood by its target of achieving 10,000 OCS transplant cases annually in the U.S. by 2028.

A group of health care workers.

Image source: Getty Images.

What's next for TransMedics

TransMedics' guidance calls for a solid finish to the year. It sees full-year revenue of $425 million-$445 million, which represents 76%-84% growth. At the midpoint, that was weaker than the consensus at $444.4 million, but it may reflect the underwhelming third-quarter results.

Overall, the results were disappointing, and the sell-off is understandable. But the quarter shouldn't affect the long-term performance of the business. In fact, the price cut looks like a buying opportunity if the biotech company continues to disrupt the organ transplant market.

Should you invest $1,000 in TransMedics Group right now?

Before you buy stock in TransMedics Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $892,313!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of November 4, 2024

Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold hit a one-year low while central banks bought 321 tonnes — the sellers were never the ones you thinkSpot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
Author  Irene Q.
Nov 13, Fri
Spot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
Nov 16, Mon
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Nov 16, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
Nov 16, Mon
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
18 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
goTop
quote